AR031431A1 - Combinacion de agonistas de gaba e inhibidores de sorbitol-deshidrogenasa - Google Patents
Combinacion de agonistas de gaba e inhibidores de sorbitol-deshidrogenasaInfo
- Publication number
- AR031431A1 AR031431A1 ARP010105541A ARP010105541A AR031431A1 AR 031431 A1 AR031431 A1 AR 031431A1 AR P010105541 A ARP010105541 A AR P010105541A AR P010105541 A ARP010105541 A AR P010105541A AR 031431 A1 AR031431 A1 AR 031431A1
- Authority
- AR
- Argentina
- Prior art keywords
- diabetic
- prodrug
- combinations
- deshidrogenasa
- sorbitol
- Prior art date
Links
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000651 prodrug Substances 0.000 abstract 4
- 229940002612 prodrug Drugs 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010007749 Cataract diabetic Diseases 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 abstract 1
- 206010063547 Diabetic macroangiopathy Diseases 0.000 abstract 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010056340 Diabetic ulcer Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 201000009101 diabetic angiopathy Diseases 0.000 abstract 1
- 201000007025 diabetic cataract Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a composiciones farmacéuticas que comprenden combinaciones de un agonista de GABA, un profármaco del mismo o una sal farmacéuticamente aceptable de dicho agonista de GABA o dicho profármaco y un SDI, un profármaco del mismo o una sal farmacéuticamente aceptable de dicho SDI o dicho profármaco, estuches que contienen tales combinaciones y métodos para utilizar tales combinaciones en el tratamiento de mamíferos, incluidos los seres humanos, que padecen complicaciones de la diabetes tales como neuropatía diabética, nefropatía diabética, cardiomiopatía diabética, retinopatía diabética, microangiopatía diabética, macroangiopatía diabética, cataratas o ulceras de los pies.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25006900P | 2000-11-30 | 2000-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR031431A1 true AR031431A1 (es) | 2003-09-24 |
Family
ID=22946187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010105541A AR031431A1 (es) | 2000-11-30 | 2001-11-28 | Combinacion de agonistas de gaba e inhibidores de sorbitol-deshidrogenasa |
Country Status (38)
Country | Link |
---|---|
US (1) | US6544998B2 (es) |
EP (1) | EP1337271B1 (es) |
JP (1) | JP2004514699A (es) |
KR (1) | KR20030059290A (es) |
CN (1) | CN1477975A (es) |
AP (1) | AP2001002360A0 (es) |
AR (1) | AR031431A1 (es) |
AT (1) | ATE281181T1 (es) |
AU (1) | AU2002215159A1 (es) |
BG (1) | BG107774A (es) |
BR (1) | BR0115783A (es) |
CA (1) | CA2430298A1 (es) |
CR (1) | CR6964A (es) |
CZ (1) | CZ20031399A3 (es) |
DE (1) | DE60106968T2 (es) |
DO (1) | DOP2001000289A (es) |
EA (1) | EA200300432A1 (es) |
EC (1) | ECSP034624A (es) |
EE (1) | EE200300248A (es) |
ES (1) | ES2230378T3 (es) |
HR (1) | HRP20030420A2 (es) |
HU (1) | HUP0302160A3 (es) |
IL (1) | IL155704A0 (es) |
IS (1) | IS6786A (es) |
MA (1) | MA26964A1 (es) |
MX (1) | MXPA03004870A (es) |
NO (1) | NO20032441L (es) |
OA (1) | OA12534A (es) |
PA (1) | PA8534101A1 (es) |
PE (1) | PE20020597A1 (es) |
PL (1) | PL365927A1 (es) |
PT (1) | PT1337271E (es) |
SK (1) | SK6192003A3 (es) |
SV (1) | SV2003000751A (es) |
TN (1) | TNSN01169A1 (es) |
UY (1) | UY27042A1 (es) |
WO (1) | WO2002043762A2 (es) |
ZA (1) | ZA200303381B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL189872B1 (pl) | 1996-07-24 | 2005-10-31 | Warner Lambert Co | Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu |
US6992109B1 (en) * | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
US7022678B2 (en) * | 2001-03-30 | 2006-04-04 | Warner-Lambert Company | Pregabalin lactose conjugates |
OA12604A (en) * | 2001-05-25 | 2006-06-08 | Warner Lambert Co | Liquid pharmaceutical composition. |
CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
KR20050036195A (ko) * | 2003-10-15 | 2005-04-20 | 고재영 | 신규한 망막병증 치료제 조성물 |
US8007827B2 (en) * | 2004-04-02 | 2011-08-30 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties |
US20050226927A1 (en) * | 2004-04-02 | 2005-10-13 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist |
KR20070020022A (ko) * | 2004-04-02 | 2007-02-16 | 임팩스 라보라토리즈, 인코포레이티드 | Gaba 수용체 효능제에 대한 제어 방출 제형 |
US20050220873A1 (en) * | 2004-04-02 | 2005-10-06 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist |
GB0420831D0 (en) | 2004-09-17 | 2004-10-20 | Glaxo Group Ltd | Novel compounds |
MX2007010076A (es) | 2005-02-17 | 2007-10-16 | Astellas Pharma Inc | Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo. |
GB0513553D0 (en) * | 2005-07-01 | 2005-08-10 | Fond D Amico Per La Ricerca Su | Rab3a |
EP2142529B1 (en) | 2007-04-27 | 2013-12-25 | Purdue Pharma LP | Trpv1 antagonists and uses thereof |
JP5452494B2 (ja) * | 2007-10-09 | 2014-03-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンフォチアミンと1または2種以上の医薬活性剤とを含む神経因性の疼痛状態の処置のための医薬組成物 |
EP2116618A1 (en) | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnosis and treatment of Kawasaki disease |
JP5815552B2 (ja) | 2009-12-08 | 2015-11-17 | ケース ウェスタン リザーブ ユニバーシティCase Westernreserve University | 眼疾患を治療する化合物および方法 |
WO2012050907A2 (en) * | 2010-09-28 | 2012-04-19 | The Regents Of The University Of California | Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes |
RU2621708C2 (ru) | 2011-06-22 | 2017-06-07 | ПУРДЬЮ ФАРМА Эл. Пи. | Антагонисты trpv1, включающие дигидроксигруппу в качестве заместителя, и их применение |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
CN114206349A (zh) | 2019-04-17 | 2022-03-18 | 指南针探路者有限公司 | 治疗神经认知障碍、慢性疼痛及减轻炎症的方法 |
SG11202111822QA (en) * | 2019-05-07 | 2021-11-29 | Univ Miami | Treatment and detection of inherited neuropathies and associated disorders |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2409754A (en) | 1946-10-22 | Method for obtaining hydantoins | ||
CH449645A (de) | 1963-07-09 | 1968-01-15 | Ciba Geigy | Verfahren zur Herstellung neuer Aminosäuren |
CH427803A (de) | 1963-12-06 | 1967-01-15 | Geigy Ag J R | Verfahren zur Herstellung eines neuen Isoxazolderivates |
DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
US3960927A (en) | 1975-03-18 | 1976-06-01 | Richardson-Merrell Inc. | Olefinic derivatives of amino acids |
FR2319338A1 (fr) * | 1975-08-01 | 1977-02-25 | Synthelabo | Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent |
GR68380B (es) | 1979-06-01 | 1981-12-28 | Wellcome Found | |
FR2492258A1 (fr) * | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
DK288385D0 (da) | 1985-06-26 | 1985-06-26 | Novo Industri As | Aminosyrederivater |
US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
KR950703539A (ko) * | 1992-09-28 | 1995-09-20 | 알렌 제이. 스피겔 | 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications) |
AU3503300A (en) * | 1999-02-24 | 2000-09-14 | Regents Of The University Of California, The | Gaba receptors mediate inhibition of t cell responses |
WO2000059510A1 (en) * | 1999-04-01 | 2000-10-12 | Pfizer Products Inc. | Aminopyrimidines as sorbitol dehydrogenase inhibitors |
ATE264311T1 (de) * | 1999-04-01 | 2004-04-15 | Pfizer Prod Inc | Verbindungen zur behandlung und vorsorge bei diabetes |
-
2001
- 2001-11-19 KR KR10-2003-7007237A patent/KR20030059290A/ko not_active Application Discontinuation
- 2001-11-19 AT AT01983739T patent/ATE281181T1/de not_active IP Right Cessation
- 2001-11-19 EA EA200300432A patent/EA200300432A1/ru unknown
- 2001-11-19 EP EP01983739A patent/EP1337271B1/en not_active Expired - Lifetime
- 2001-11-19 HU HU0302160A patent/HUP0302160A3/hu unknown
- 2001-11-19 DO DO2001000289A patent/DOP2001000289A/es unknown
- 2001-11-19 AU AU2002215159A patent/AU2002215159A1/en not_active Abandoned
- 2001-11-19 CZ CZ20031399A patent/CZ20031399A3/cs unknown
- 2001-11-19 JP JP2002545732A patent/JP2004514699A/ja not_active Withdrawn
- 2001-11-19 AP APAP/P/2001/002360A patent/AP2001002360A0/en unknown
- 2001-11-19 IL IL15570401A patent/IL155704A0/xx unknown
- 2001-11-19 CA CA002430298A patent/CA2430298A1/en not_active Abandoned
- 2001-11-19 PT PT01983739T patent/PT1337271E/pt unknown
- 2001-11-19 CN CNA018195946A patent/CN1477975A/zh active Pending
- 2001-11-19 BR BR0115783-3A patent/BR0115783A/pt not_active IP Right Cessation
- 2001-11-19 MX MXPA03004870A patent/MXPA03004870A/es unknown
- 2001-11-19 PL PL01365927A patent/PL365927A1/xx not_active Application Discontinuation
- 2001-11-19 EE EEP200300248A patent/EE200300248A/xx unknown
- 2001-11-19 DE DE60106968T patent/DE60106968T2/de not_active Expired - Fee Related
- 2001-11-19 ES ES01983739T patent/ES2230378T3/es not_active Expired - Lifetime
- 2001-11-19 OA OA1200300142A patent/OA12534A/en unknown
- 2001-11-19 SK SK619-2003A patent/SK6192003A3/sk unknown
- 2001-11-19 WO PCT/IB2001/002213 patent/WO2002043762A2/en not_active Application Discontinuation
- 2001-11-27 UY UY27042A patent/UY27042A1/es not_active Application Discontinuation
- 2001-11-28 PE PE2001001191A patent/PE20020597A1/es not_active Application Discontinuation
- 2001-11-28 AR ARP010105541A patent/AR031431A1/es unknown
- 2001-11-29 TN TNTNSN01169A patent/TNSN01169A1/fr unknown
- 2001-11-29 US US09/997,038 patent/US6544998B2/en not_active Expired - Fee Related
- 2001-11-29 SV SV2001000751A patent/SV2003000751A/es unknown
- 2001-11-30 PA PA20018534101A patent/PA8534101A1/es unknown
-
2003
- 2003-04-14 IS IS6786A patent/IS6786A/is unknown
- 2003-04-24 CR CR6964A patent/CR6964A/es not_active Application Discontinuation
- 2003-04-30 ZA ZA200303381A patent/ZA200303381B/en unknown
- 2003-05-07 BG BG107774A patent/BG107774A/xx unknown
- 2003-05-20 MA MA27165A patent/MA26964A1/fr unknown
- 2003-05-22 HR HR20030420A patent/HRP20030420A2/hr not_active Application Discontinuation
- 2003-05-27 EC EC2003004624A patent/ECSP034624A/es unknown
- 2003-05-28 NO NO20032441A patent/NO20032441L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR031431A1 (es) | Combinacion de agonistas de gaba e inhibidores de sorbitol-deshidrogenasa | |
AR031432A1 (es) | Combinacion de agonistas de gaba e inhibidores de aldosa-reductasa | |
AR067347A1 (es) | Combinacion antihelmintica | |
GT200500173A (es) | Compuestos de heteroaril- y fenilsulfamoilo sustituidos | |
ES2581331T3 (es) | Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática | |
ES2487496T3 (es) | Agente para aliviar el síndrome metabólico | |
CL2022001583A1 (es) | Derivados espiráncos sustituidos de cadena lineal | |
CL2008002227A1 (es) | Compuestos derivados de 4-[(8r)-4-amino-5-oxo-7,8-dihidrorimido[5,4-f][1,4]oxazepin-6(5h)-il]fenilo sustituido; su composicion farmaceutica; y uso de los compuestos en el tratamiento de la diabetes de tipo 2, utiles particularmente para tratar la obesidad. | |
CR11418A (es) | Trans-clomifeno para el sindrome metabolico | |
AR067903A1 (es) | Metodo para tratar la depresion mediada por estres | |
CL2011000851A1 (es) | Composicion farmaceutica que comprende al menos una insulina y al menos un agonista de glp-1; metodo de preparacion; su uso para tratar diabetes o prevenir la disfuncion de celulas beta pancreaticas; kit; y dispositivo. | |
CL2010000188A1 (es) | Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso. | |
GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
CL2011001131A1 (es) | Uso de una formulacion que sirve para preparar un medicamento para una inyeccion, que reduce al minimo la inflamacion en el sitio de la inyeccion de un anticuerpo, y donde la formulacion comprendeun anticuerpo 2h7 y variantes del anticuerpo y polivinilpirrolidona (pvp) | |
CL2008003576A1 (es) | Compuestos derivados de amida del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico; composicion farmaceutica que los comprende; y usos en el tratamiento de una afeccion inflamatoria. | |
ES2552654T3 (es) | Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos | |
ES2582660T3 (es) | Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina | |
AR056517A1 (es) | Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa | |
CL2008001477A1 (es) | Composicion farmaceutica compuesta por la combinacion sinergica de un agente anticonvulsivante como gabapentina y un agente antiinflamatorio no esteroideo como meloxicam, los rangos de concentracion presentes para la gabapentina son 3 a 300 mg y de 0,1 a 30 mg para meloxicam; y uso para tratar el dolor neuropatico | |
AR033596A1 (es) | Composicion farmaceutica para inyeccion intramuscular que contiene loxoprofeno | |
AR046213A1 (es) | Forma de presentacion del naproxeno sodico | |
AR067351A1 (es) | Combinacion de picotamida con nafronil | |
GT200500042A (es) | Compuestos de heteroaril- y fenilsulfamoilo sustituidos | |
AR048355A1 (es) | Asociacion entre un compuesto heterociclico y un agente antioxidante y las composiciones farmaceuticas que los contienen | |
AR061046A1 (es) | Mirtazapina para el tratamiento del dolor neuropatico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |